Physician profile
Adam Harless
NPI 1851653315
$10,661.31
in general payments reported to CMS, 2019-2025
32 companies · $1,505 in 2025
The $1,505 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,056 · 2020: $1,150 · 2021: $936 · 2022: $535 · 2023: $190 · 2024: $1,289 · 2025: $1,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,088 · Travel and Lodging: $864 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,087.99 |
| Travel and Lodging | $863.71 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,504.97 | 2019-2025 | Avvigo Guidance System, Farapulse, Watchman Flx |
| Abbott Laboratories | $1,495.53 | 2020-2025 | Triclip, Esprit, Supera |
| Medtronic Vascular, INC. | $1,425.26 | 2019-2020 | |
| Inari Medical, INC. | $1,026.28 | 2020-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Medtronic, INC. | $455.85 | 2022-2025 | Corevalve Evolut R, Symplicity G3, Cobalt Dr Mri Surescan |
| Novartis Pharmaceuticals Corporation | $311.84 | 2022-2025 | |
| Shockwave Medical, INC | $270.56 | 2020-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $243.55 | 2019-2023 | Impella |
| Edwards Lifesciences Corporation | $236.13 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $192.66 | 2019-2022 | |
| Pfizer INC. | $181.28 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.20 | 2021-2025 | Jardiance |
| Philips North America LLC | $160.49 | 2024 | (Az7) Lasers, (Br5) Peripheral Ivus |
| Penumbra, INC. | $123.12 | 2021-2022 | |
| Bard Peripheral Vascular, INC. | $122.08 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $115.39 | 2019 | |
| Cardiovascular Systems INC. | $107.80 | 2020 | |
| Chiesi USA, INC. | $104.18 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $76.64 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $43.23 | 2022 | |
| W. L. Gore & Associates, INC. | $42.74 | 2019-2021 | |
| Recor Medical INC | $39.26 | 2025 | Paradise Ultrasound Renal Denervation System |
| Novo Nordisk INC | $32.27 | 2024 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $29.43 | 2023-2025 | Eliquis |
| Cardiva Medical, INC. | $21.84 | 2024 | Savvywire |
| Amgen INC. | $20.27 | 2021 | |
| Bracco Diagnostics INC. | $20.07 | 2022 | |
| Atricure, INC. | $19.28 | 2021 | |
| Biosense Webster, INC. | $19.21 | 2025 | Carto 3 |
| Stryker Corporation | $16.09 | 2025 | Artix Mt |
| Ge Healthcare | $15.78 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.03 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Harless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.